Claims for Patent: 10,385,399

Summary for Patent: 10,385,399

Title:	Method for determining clinically relevant hypoxia in cancer
Abstract:	The present invention provides a method for determining the oxygen status of a cancer of an individual. The method comprise determining the transcriptional expression level of ADM (SEQ ID No:1), and/or at least one gene selected from ANKRD37 (SEQ ID NO.: 3), P4HA2 (SEQ ID NO.: 12), NDRG1 (SEQ ID NO: 10), SLC2A1 (SEQ ID NO:15), P4HA1 (SEQ ID NO.: 11), LOX (SEQ ID NO.: 9), C3orf28 (SEQ ID NO.: 6), BNIP3L (SEQ ID NO.: 5), BNIP3 (SEQ ID NO.:4), EGLN3 (SEQ ID NO.: 7), PDK1 (SEQ ID NO.: 13), PFKFB3 (SEQ ID NO.: 14), KCTD11 (SEQ ID NO.: 8), and/or ALDOA (SEQ ID NO.: 2), in a cancer sample. The transcriptional level is then correlated to the transcriptional level to at least one reference gene, and oxygen status 10 is then evaluated by comparing the correlated transcription level with a predetermined reference sample comprising cancer cells characterized by a high oxygen level.
Inventor(s):	Overgaard; Jens (Aarhus C, DK), Sorensen; Brita Singers (Hjortshoj, DK), Alsner; Jan (Hojbjerg, DK), Wiuf; Carsten (Kobenhavn O, DK), Nordsmark; Marianne (Risskov, DK), Toustrup; Kasper (Hojbjerg, DK)
Assignee:	AARHUS UNIVERSITET (Aarhus, DK)
Application Number:	14/114,496
Patent Claims:	1. A method for the amelioration and/or treatment of cancer in an individual comprising the steps of: a) providing a sample of a cancer from said individual, b) determining the oxygen status of said cancer by: i) determining the transcriptional expression level of the ADM gene (SEQ ID NO: 1), ii) correlating said transcriptional expression level of the ADM gene to the expression level of one or more reference genes selected from the group consisting of ACTR3 (SEQ ID NO: 53), NDFIP1 (SEQ ID NO: 54), and RPL37A (SEQ ID NO: 55), and iii) characterizing the oxygen status of said cancer by comparing the correlated transcriptional expression level of ii) with a predetermined correlated transcriptional expression level of ADM, and c) if said individual has a cancer comprising a region for which the oxygen status is characterized by low oxygen level below 20 mm Hg, then administer a hypoxia-modifying agent in a therapeutically effective amount to said individual or if said individual has a cancer comprising a region for which the oxygen status is characterized by high oxygen level 20 mm Hg or higher, then subjecting said individual to radiation therapy without administering a hypoxia-modifying agent. 2. The method according to claim 1, wherein said hypoxia-modifying agent is selected from the group consisting of HBO, Carbogen, ARCON, blood transfusion, EPO, 2,3-DPG, 2,3-diphosphoglycerate, Nicotinamide, MMC, TPZ, AQ4N, PR-104, LCQ-1, RH1, indisulam, sulfonamides, sulfamates, sulfamides, oncolytic bacteria, avastin, DC101, thymidine kinase inhibitors, CA40 OXi4503, DMXAA, nimorazole, MISO and DORA. 3. The method according to claim 1, said method further comprising subjected subjecting said individual having a cancer comprising a region for which the oxygen status is characterized by low oxygen level below 20 mm Hg to radiation therapy. 4. The method according to claim 3, wherein said radiation therapy occurs as one or more fractions. 5. The method according to claim 3, wherein the hypoxia-modifying agent is administered prior to or simultaneously with said radiation therapy. 6. The method according to claim 1, wherein the method furthermore comprises a step of administering an additional compound. 7. The method according to claim 6, wherein said additional compound is anti-proliferative and/oranti-neoplastic agents. 8. The method according to claim 6, wherein said additional compound is a radiosensitizing drug. 9. The method according to claim 1, wherein said predetermined correlated transcriptional expression level in step b iii) is a predetermined reference sample comprising cancer cells characterized by a high oxygen level 20 mm Hg or higher and a predetermined reference sample comprising cancer cells characterized by a low oxygen level below 20 mm Hg. 10. The method according to claim 1, wherein said radiation therapy that is applied to said individual having a cancer comprising a region for which the oxygen status is characterized by high oxygen level 20 mm Hg or higher occurs as one or more fractions. 11. The method according to claim 1, wherein the cancer is a planocellular cancer or an adenocarcinoma. 12. The method according to claim 1, wherein said cancer is squamous cellular cancer. 13. The method according to claim 12, wherein the squamous cellular cancer is head and neck cancer. 14. The method according to claim 1, said method further comprising in step b) determining the oxygen status of said cancer by: iv) determining the transcriptional expression level of at least one additional gene selected from the group consisting of ANKRD37 (SEQ ID NO: 3), P4HA2 (SEQ ID NO: 12), NDRG1 (SEQ ID NO: 10), SLC2A (SEQ ID NO: 1), P4HA1 (SEQ ID NO: 11), LOX (SEQ ID NO: 9), C3orf28 (SEQ ID NO: 6), BNIP3L (SEQ ID NO: 5), BNIP3 (SEQ ID NO: 4), EGLN3 (SEQ ID NO: 7), PDK1 (SEQ ID NO: 13), PFKFB3 (SEQ ID NO: 14), KCTD11 (SEQ ID NO: 8), and (ALDOA (SEQ ID NO: 2), v) correlating said additional transcriptional expression level of the ADM gene and said at least one additional gene to the expression level of the one or more reference genes, and vi) characterizing the oxygen status of said cancer by comparing the correlated transcriptional expression level of v) with a predetermined correlated transcriptional expression level of ADM and said at least one additional gene. 15. The method according to claim 14, wherein the transcriptional expression level of at least ADM (SEQ ID NO: 1), ANKRD37 (SEQ ID NO: 3), P4HA2 (SEQ ID NO: 12), and NDRG1 (SEQ ID NO: 10) are determined in step iv). 16. The method according to claim 14, wherein the transcriptional expression level of at least ADM (SEQ ID NO: 1), ANKRD37 (SEQ ID NO: 3), P4HA2 (SEQ ID NO: 12), NDRG1 (SEQ ID NO: 10), SLC2A1 (SEQ ID NO: 15), P4HA1 (SEQ ID NO: 11), LOX (SEQ ID NO: 9), and C3orf28 (SEQ ID NO: 6) are determined in step iv).

Details for Patent 10,385,399

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2031-04-29